Simcere Pharmaceutical Group Limited
2096
Helyezés a részvények között
#4476
Simcere Pharmaceutical Group Limited is a Chinese entity engaged in the... Simcere Pharmaceutical Group Limited is a Chinese entity engaged in the comprehensive process of discovering, developing, manufacturing, and commercializing pharmaceutical products. These medicines are distributed to various clients, including distributors, pharmacy chains, and fellow drug manufacturers within China. The company strategically focuses on a diverse range of therapeutic areas, notably oncology, central nervous system conditions, autoimmune diseases, anti-infective treatments, and cardiovascular health, among others. Its extensive product portfolio features key medications such as Sanbexin (an edaravone and dexborneol concentrated solution for injection), Endostar (a recombinant human endostatin injection), ENWEIDA (an envafolimab injection), Softan (rosuvastatin calcium tablets), ZAILIN (amoxicillin in granules, dispersible tablets, or capsules), Iremod (iguratimod tablets), Antine (diclofenac sodium sustained-release capsules or gel), and Orencia (an abatacept injection). Additionally, Simcere offers specialized promotional services for pharmaceutical goods. Demonstrating its commitment to innovation, the group has established a strategic regional licensing collaboration with Vivoryon Therapeutics N.V. This partnership aims to develop and commercialize novel therapies for Alzheimer's disease by targeting the neurotoxic amyloid protein N3pE (pGlu-Aß). Established in 1995, Simcere Pharmaceutical Group Limited is headquartered in Nanjing, China.
Részvényárfolyam
$1.32
Piaci kapitalizáció
$3.40B
Változás (1 nap)
-4.51%
Változás (1 év)
-19.88%
Ország
CN
Kereskedés Simcere Pharmaceutical Group Limited (2096)
Kategória
Healthcare
EPS Simcere Pharmaceutical Group Limited (2096) részvényre
EPS 2026 dátummal, TTM: 0
Simcere Pharmaceutical Group Limited legfrissebb pénzügyi jelentései és részvényára alapján a vállalat jelenlegi EPS mutatója (TTM) 0. 2026 végén a vállalat EPS mutatója 0 volt, megegyezik a 2026 év EPS értékéhez, amely 0 volt.
Simcere Pharmaceutical Group Limited EPS története 2012 és 2026 között
EPS minden év végén
| Év | EPS | Változtassa meg |
|---|---|---|
| 2025 | $0.08 | 94.46% |
| 2024 | $0.04 | 4.20% |
| 2023 | $0.04 | -27.01% |
| 2022 | $0.05 | -42.83% |
| 2021 | $0.09 | 129.40% |
| 2020 | $0.04 | -28.93% |
| 2019 | $0.06 | 37.59% |
| 2018 | $0.04 | 103.50% |
| 2017 | $0.02 | -76.47% |
| 2012 | $0.09 | 0.00% |
EPS hasonló cégek vagy versenytársak esetén
| Vállalat | EPS | EPS különbség | Ország |
|---|---|---|---|
| $17.32 | - |
US
|
|
| $-7.98 | - |
US
|
|
| $-5.29 | - |
AU
|
|
| $27.74 | - |
NL
|
|
| $13.70 | - |
BE
|
